Pancreatic Stone Protein in Co-Evaluation With QSOFA and News2 for Early Sepsis Detection at the Emergency Department
Abstract
Background: Early sepsis identification at the emergency department (ED) triage is essential for timely treatment and improved outcomes. This study evaluated the diagnostic performance of pancreatic stone protein (PSP) in combination with the quick Sequential Organ Failure Assessment (qSOFA) and the National Early Warning Score (NEWS2) for early sepsis detection.
Methods: As part of the PROMPT study-a noninterventional, multicenter trial across six Greek hospitals-blood samples were collected within the first hour of admission in the emergency department. PSP levels were retrospectively assessed using a nanofluidic near-patient immunoassay device (abioSCOPE, Abionic SA, Switzerland) in 362 adult patients with suspected infections and evaluated their qSOFA and NEWS2 scores. Objectives included evaluating qSOFA's performance, assessing the performance of PSP to identify high-risk patients with qSOFA ≤1, and determining the added value of combining PSP with qSOFA or NEWS2 (cutoff ≥7), using standard performance metrics.
Results: Among 156 sepsis cases, 128 (82.1%) had qSOFA scores ≤1. A qSOFA score ≥2 demonstrated sensitivity 17.9% and specificity 97.1% for sepsis diagnosis. In comparison, a qSOFA score of 1 showed a sensitivity of 44.2% and a specificity of 63.6%, while a score of 0 yielded a sensitivity of 37.8% and a specificity of 39.3%. The addition of PSP (cutoff: 300 ng/mL) to qSOFA ≤1 improved specificity to 94.0%, with a sensitivity of 14.8%-closely mirroring the…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 362 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.